Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Retained Earnings (2020 - 2025)

Rani Therapeutics Holdings has reported Retained Earnings over the past 6 years, most recently at -$132.6 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$132.6 million for Q4 2025, down 2651700.0% from a year ago — trailing twelve months through Dec 2025 was -$132.6 million (down 2651700.0% YoY), and the annual figure for FY2025 was -$132.6 million, down 2651700.0%.
  • Retained Earnings for Q4 2025 was -$132.6 million at Rani Therapeutics Holdings, down from $3000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for RANI hit a ceiling of $8000.0 in Q3 2024 and a floor of -$132.6 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$38.7 million (2022), compared with a mean of -$47.5 million.
  • Biggest five-year swings in Retained Earnings: surged 100.01% in 2024 and later tumbled 2651700.0% in 2025.
  • Rani Therapeutics Holdings' Retained Earnings stood at -$3.1 million in 2021, then surged by 97.68% to -$73000.0 in 2022, then tumbled by 99747.95% to -$72.9 million in 2023, then skyrocketed by 100.01% to $5000.0 in 2024, then tumbled by 2651700.0% to -$132.6 million in 2025.
  • The last three reported values for Retained Earnings were -$132.6 million (Q4 2025), $3000.0 (Q3 2025), and -$116.9 million (Q2 2025) per Business Quant data.